scholarly journals The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Zeinab Ghorbani ◽  
Pegah Rafiee ◽  
Akbar Fotouhi ◽  
Samane Haghighi ◽  
Reyhaneh Rasekh Magham ◽  
...  
Keyword(s):  
Vitamin D ◽  
Controlled Trial ◽  
Serum Levels ◽  
Episodic Migraine ◽  
Vitamin D Supplementation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Hoc Analysis ◽  
Calcitonin Gene ◽  
Post Hoc

scholarly journals Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1987
Author(s):  
Makoto Morita ◽  
Mai Okuyama ◽  
Taisuke Akutsu ◽  
Hironori Ohdaira ◽  
Yutaka Suzuki ◽  
...  
Keyword(s):  
Vitamin D ◽  
Digestive Tract ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Double Blind ◽  
Digestive Tract Cancer ◽  
Post Hoc Analysis ◽  
Tract Cancer ◽  
Postoperative Serum ◽  
Post Hoc

Because vitamin D responsive elements have been found to be located in the PD-L1 gene, vitamin D supplementation was hypothesized to regulate serum PD-L1 levels and thus alter survival time of cancer patients. A post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative vitamin D3 supplementation (2000 IU/day) in 417 patients with stage I to stage III digestive tract cancer from the esophagus to the rectum was conducted. Postoperative serum PD-L1 levels were measured by ELISA and divided into quintiles (Q1–Q5). Serum samples were available for 396 (95.0%) of the original trial. Vitamin D supplementation significantly (p = 0.0008) up-regulated serum PD-L1 levels in the lowest quintile (Q1), whereas it significantly (p = 0.0001) down-regulated them in the highest quintile (Q5), and it did not either up- or down-regulate them in the middle quintiles (Q2–Q4). Significant effects of vitamin D supplementation, compared with placebo on death (HR, 0.34; 95% CI, 0.12–0.92) and relapse/death (HR, 0.37; 95% CI, 0.15–0.89) were observed in the highest quintile (Q5) of serum PD-L1, whereas significant effects were not observed in other quintiles (Pinteraction = 0.02 for death, Pinteraction = 0.04 for relapse/death). Vitamin D supplementation significantly reduced the risk of relapse/death to approximately one-third in the highest quintile of serum PD-L1.

scholarly journals Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1465
Author(s):  
Taisuke Akutsu ◽  
Eisaku Ito ◽  
Mitsuo Narita ◽  
Hironori Ohdaira ◽  
Yutaka Suzuki ◽  
...  
Keyword(s):  
Vitamin D ◽  
Digestive Tract ◽  
Multivariate Analyses ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Digestive Tract Cancer ◽  
Post Hoc Analysis ◽  
Tract Cancer ◽  
Potential Biomarker ◽  
Post Hoc

Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; p = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse.

Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial

2019 ◽  
Vol 54 (3) ◽  
pp. 298-307
Author(s):  
Mehar G Kang ◽  
Hong Qian ◽  
Kamyar Keramatian ◽  
Trisha Chakrabarty ◽  
Gayatri Saraf ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Atypical Antipsychotic ◽  
Maintenance Treatment ◽  
Atypical Antipsychotics ◽  
Controlled Trial ◽  
Hazard Ratio ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Hoc Analysis ◽  
Post Hoc

Objective: Lithium and valproate are commonly used either in monotherapy or in combination with atypical antipsychotics in maintenance treatment of bipolar I disorder; however, their comparative efficacy is not well understood. This study aimed to compare the efficacy of valproate and lithium on mood stability either in monotherapy or in combination with atypical antipsychotics. Methods: We performed a post hoc analysis using data from a 52-week randomized double-blind, placebo-controlled trial, that recruited 159 patients with recently remitted mania during treatment with lithium or valproate and adjunctive atypical antipsychotic therapy. Patients were randomized to discontinue adjunctive atypical antipsychotic at 0, 24 or 52 weeks. Results: No significant differences in efficacy were observed between valproate and lithium (hazard ratio: 0.99; 95% confidence interval: [0.66, 1.48]) in time to any mood event. Valproate with 24 weeks of atypical antipsychotic was significantly superior to valproate monotherapy in preventing any mood relapse (hazard ratio: 0.46; 95% confidence interval: [0.22, 0.97]) while lithium with 24 weeks of atypical antipsychotic was superior to lithium monotherapy in preventing mania (hazard ratio: 0.27; 95% confidence interval: [0.09, 0.85]) but not depression. Conclusion: Overall, this study did not find significant differences in efficacy between the two mood-stabilizing agents when used as monotherapy or in combination with atypical antipsychotics. However, study design and small sample size might have precluded from detecting an effect if true difference in efficacy existed. Further head-to-head investigations with stratified designs are needed to evaluate maintenance therapies.

Clinical and Metabolic Response to Vitamin D Supplementation in Endometrial Hyperplasia: a Randomized, Double-Blind, Placebo-Controlled Trial

2017 ◽  
Vol 8 (3) ◽  
pp. 185-195 ◽  
Author(s):  
Zohreh Tabassi ◽  
Sedigheh Bagheri ◽  
Mansooreh Samimi ◽  
Hamid Reza Gilasi ◽  
Fereshteh Bahmani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Endometrial Hyperplasia ◽  
Metabolic Response ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease

2013 ◽  
Vol 97 (5) ◽  
pp. 1004-1013 ◽  
Author(s):  
Masahiko Suzuki ◽  
Masayuki Yoshioka ◽  
Masaya Hashimoto ◽  
Maiko Murakami ◽  
Miki Noya ◽  
...  
Keyword(s):  
Vitamin D ◽  
Parkinson Disease ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document